Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy

Cancer Research

Volumn 73, Issue 12, 2013, Pages 3534-3544

  Wilkie, Kathleen P ^a   Hahnfeldt, Philip ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CONTROLLED STUDY; DORMANCY; ENVIRONMENTAL CARRYING CAPACITY; IMMUNOREGULATION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ALGORITHMS; ANIMALS; CELL COMMUNICATION; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C3H; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84879115621     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4590     Document Type: Article

References (37)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
2. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4. (Pubitemid 35231542)
3. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71. (Pubitemid 32867877)
4. de Pillis LG, Radunskaya AE, Wiseman CL. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 2005;65:7950-8. (Pubitemid 41297274)
5. Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005;105: 2428-35. (Pubitemid 40387042)
6. Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004;104:2124-33. (Pubitemid 39297867)
7. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24-37. (Pubitemid 43053650)
8. Liotta L, Kohn E. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
9. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25. (Pubitemid 43338211)
10. Teng MWL, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008;84:988-93.
11. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360. (Pubitemid 38680426)
12. Page K, Uhr JW. Mathematical models of cancer dormancy. Leuk Lymphoma 2005;46:313-27. (Pubitemid 40220390)
13. Kuznetsov VA. Mathematical modeling of the development of dormant tumors and immune stimulation of their growth. Cybern Syst Anal 1988;23:556-64.
14. Kirschner D, Panetta JC. Modeling immunotherapy of the tumor-immune interaction. J Math Biol 1998;37:235-52.
15. Kuznetsov VA, Makalkin IA, Taylor M, Perelson AS. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 1994;56:295-321.
16. Arciero J, Jackson TL, Kirschner DE. A mathematical model of tumor-immune evasion and siRNA treatment. Discret Contin Dyn S 2004;4: 39-58. (Pubitemid 38202954)
17. Wilkie KP. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy. Adv Exp Med Biol 2013; 734:201-34.
18. d'Onofrio A. Bounded-noise-induced transitions in a tumor-immune system interplay. Phys Rev E 2010;81:021923:1-7.
19. d'Onofrio A, Ciancio A. Simple biophysical model of tumor evasion from immune system control. Phys Rev E 2011;84:031910:1-7.
20. Al-Tameemi MM, Chaplain MA, d'Onofrio A. Evasion of tumours from the control of the immune system: consequences of brief encounters. Biol Direct 2012;7:31.
21. Withers H. Treatment-induced accelerated human tumor growth. Semin Radiat Oncol 1993;3:135-43. (Pubitemid 23122121)
22. Sharouni El SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small- cell lung tumours after induction chemotherapy. Br J Cancer 2003;89:2184-9. (Pubitemid 38167997)
23. Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, Geyer FC, Reis-Filho JS, Mao J-H, et al. Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell 2011;19:640-51.
24. Tanooka H, Tanaka K, Arimoto H. Dose response and growth rates of subcutaneous tumors induced with 3-methylcholanthrene in mice and timing of tumor origin. Cancer Res 1982;42:4740-3. (Pubitemid 13205983)
25. Robert CP, Casella G. Metropolis-Hastings algorithms. Introducing Monte Carlo methods with R. Springer Science+Business Media, New York, NY; 2010. p. 167-97.
26. Cirit M, Haugh JM. Data-driven modelling of receptor tyrosine kinase signalling networks quantifies receptor-specific potencies of PI3K- and Ras-dependent ERK activation. Biochem J 2012;441:77-85.
27. Sotolongo-Costa O, Morales Molina L, Rodriguez Perez D, Antoranz J, Chacon Reyes M. Behavior of tumors under nonstationary therapy. Physica D 2003;178:242-53.
28. d'Onofrio A. A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 2005;208:220-35.
29. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky LR. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770-5. (Pubitemid 29472873)
30. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010; 2:a003244.
31. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5: 516-25. (Pubitemid 40942828)
32. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406. (Pubitemid 351609443)
33. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-4.
34. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7. (Pubitemid 350231320)
35. Saudemont A, Hamrouni A, Marchetti P, Liu J, Jouy N, Hetuin D, et al. Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 2007;67:4491-8. (Pubitemid 46815100)
36. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 2004;431:527-32. (Pubitemid 39336325)
37. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metast Rev 2010;29:309-16.